יחס שווי פעילות לרווח לפני ריבית, מסים ופחת Bone Biologics Inc (BBLG)

Bone Biologics develops advanced bioscaffolds to accelerate skeletal regeneration, restoring functionality to patients following injuries. Business valuation growth is driven by NELL-1 protein trials and interest from pharmaceutical behemoths in the company's patents. Bone Biologics is currently focusing on R&D for spinal surgery. This chart on GURU.Markets reflects a price trend with an EV/EBITDA of 0.00, confirming an active development stage.

Scaling implant trials through third-party contractors directly impacts the operating margins of Bone Biologics. This indicator compares the total enterprise value with earnings before interest, taxes, depreciation, and amortization, capturing the sensitivity of capitalization to the cost of debt. Analyzing the historical EV/EBITDA multiple of the business allows investors to determine the real value of assets, stripped of tax and debt distortions.